The Association Between the Use of Zolpidem and the Risk of Alzheimer's Disease Among Older People

Hui Ting Cheng, Fang Ju Lin, Steven R. Erickson, Jin Liern Hong, Chung Hsuen Wu

研究成果: 雜誌貢獻文章

4 引文 (Scopus)

摘要

Objectives: To evaluate the association between zolpidem use and the risk of Alzheimer's disease among older people. Design: A retrospective cohort study using data from 2001 to 2011 from the National Health Insurance Research Database. Setting: Taiwan. Participants: A total of 6,922 patients aged 65 years or older enrolled from January 2002 to December 2004 (the enrollment period). Intervention (Exposure): Zolpidem users were identified as patients who used zolpidem during the enrollment period. The index date was the date of the first zolpidem prescription. Dosage of zolpidem use was defined using cumulative defined daily dose (cDDD) based on the cumulative dosage that patients took within one year after the index date (grouped as: less than 28, 28–90, 91–180, and more than 180 cDDD). Measurements: The occurrence of Alzheimer's disease was defined as the time period from the end of one year after the index date to the date of the Alzheimer's disease diagnosis. The propensity score was used to adjust the measured confounders of Alzheimer's disease. Cox proportional hazards models were used to evaluate the association between zolpidem use and the incidence of Alzheimer's disease. Results: Zolpidem users with a high cumulative dose (>180 cDDD) in the first year after initiation had a significantly greater risk of Alzheimer's disease than non-zolpidem users (HR = 2.97, 95% CI = 1.61–5.49) and low cumulative dose (<28 cDDD) users (HR = 4.18, 95% CI = 1.77–9.86). Conclusion: We found the use of a high cumulative dose of zolpidem was associated with an increased risk of Alzheimer's disease among older people living in Taiwan. It is advised to use caution when considering long-term use of zolpidem in older patients.

原文英語
頁(從 - 到)2488-2495
頁數8
期刊Journal of the American Geriatrics Society
65
發行號11
DOIs
出版狀態已發佈 - 十一月 1 2017

指紋

Alzheimer Disease
Taiwan
zolpidem
Propensity Score
National Health Programs
Proportional Hazards Models
Prescriptions
Cohort Studies
Retrospective Studies
Databases
Incidence
Research

ASJC Scopus subject areas

  • Geriatrics and Gerontology

引用此文

The Association Between the Use of Zolpidem and the Risk of Alzheimer's Disease Among Older People. / Cheng, Hui Ting; Lin, Fang Ju; Erickson, Steven R.; Hong, Jin Liern; Wu, Chung Hsuen.

於: Journal of the American Geriatrics Society, 卷 65, 編號 11, 01.11.2017, p. 2488-2495.

研究成果: 雜誌貢獻文章

Cheng, Hui Ting ; Lin, Fang Ju ; Erickson, Steven R. ; Hong, Jin Liern ; Wu, Chung Hsuen. / The Association Between the Use of Zolpidem and the Risk of Alzheimer's Disease Among Older People. 於: Journal of the American Geriatrics Society. 2017 ; 卷 65, 編號 11. 頁 2488-2495.
@article{30371aaa48df4132a568f5d4ea917893,
title = "The Association Between the Use of Zolpidem and the Risk of Alzheimer's Disease Among Older People",
abstract = "Objectives: To evaluate the association between zolpidem use and the risk of Alzheimer's disease among older people. Design: A retrospective cohort study using data from 2001 to 2011 from the National Health Insurance Research Database. Setting: Taiwan. Participants: A total of 6,922 patients aged 65 years or older enrolled from January 2002 to December 2004 (the enrollment period). Intervention (Exposure): Zolpidem users were identified as patients who used zolpidem during the enrollment period. The index date was the date of the first zolpidem prescription. Dosage of zolpidem use was defined using cumulative defined daily dose (cDDD) based on the cumulative dosage that patients took within one year after the index date (grouped as: less than 28, 28–90, 91–180, and more than 180 cDDD). Measurements: The occurrence of Alzheimer's disease was defined as the time period from the end of one year after the index date to the date of the Alzheimer's disease diagnosis. The propensity score was used to adjust the measured confounders of Alzheimer's disease. Cox proportional hazards models were used to evaluate the association between zolpidem use and the incidence of Alzheimer's disease. Results: Zolpidem users with a high cumulative dose (>180 cDDD) in the first year after initiation had a significantly greater risk of Alzheimer's disease than non-zolpidem users (HR = 2.97, 95{\%} CI = 1.61–5.49) and low cumulative dose (<28 cDDD) users (HR = 4.18, 95{\%} CI = 1.77–9.86). Conclusion: We found the use of a high cumulative dose of zolpidem was associated with an increased risk of Alzheimer's disease among older people living in Taiwan. It is advised to use caution when considering long-term use of zolpidem in older patients.",
keywords = "Alzheimer's disease, hypnotics, National Health Insurance Research Database (NHIRD), Taiwan, zolpidem",
author = "Cheng, {Hui Ting} and Lin, {Fang Ju} and Erickson, {Steven R.} and Hong, {Jin Liern} and Wu, {Chung Hsuen}",
year = "2017",
month = "11",
day = "1",
doi = "10.1111/jgs.15018",
language = "English",
volume = "65",
pages = "2488--2495",
journal = "Journal of the American Geriatrics Society",
issn = "0002-8614",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "11",

}

TY - JOUR

T1 - The Association Between the Use of Zolpidem and the Risk of Alzheimer's Disease Among Older People

AU - Cheng, Hui Ting

AU - Lin, Fang Ju

AU - Erickson, Steven R.

AU - Hong, Jin Liern

AU - Wu, Chung Hsuen

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Objectives: To evaluate the association between zolpidem use and the risk of Alzheimer's disease among older people. Design: A retrospective cohort study using data from 2001 to 2011 from the National Health Insurance Research Database. Setting: Taiwan. Participants: A total of 6,922 patients aged 65 years or older enrolled from January 2002 to December 2004 (the enrollment period). Intervention (Exposure): Zolpidem users were identified as patients who used zolpidem during the enrollment period. The index date was the date of the first zolpidem prescription. Dosage of zolpidem use was defined using cumulative defined daily dose (cDDD) based on the cumulative dosage that patients took within one year after the index date (grouped as: less than 28, 28–90, 91–180, and more than 180 cDDD). Measurements: The occurrence of Alzheimer's disease was defined as the time period from the end of one year after the index date to the date of the Alzheimer's disease diagnosis. The propensity score was used to adjust the measured confounders of Alzheimer's disease. Cox proportional hazards models were used to evaluate the association between zolpidem use and the incidence of Alzheimer's disease. Results: Zolpidem users with a high cumulative dose (>180 cDDD) in the first year after initiation had a significantly greater risk of Alzheimer's disease than non-zolpidem users (HR = 2.97, 95% CI = 1.61–5.49) and low cumulative dose (<28 cDDD) users (HR = 4.18, 95% CI = 1.77–9.86). Conclusion: We found the use of a high cumulative dose of zolpidem was associated with an increased risk of Alzheimer's disease among older people living in Taiwan. It is advised to use caution when considering long-term use of zolpidem in older patients.

AB - Objectives: To evaluate the association between zolpidem use and the risk of Alzheimer's disease among older people. Design: A retrospective cohort study using data from 2001 to 2011 from the National Health Insurance Research Database. Setting: Taiwan. Participants: A total of 6,922 patients aged 65 years or older enrolled from January 2002 to December 2004 (the enrollment period). Intervention (Exposure): Zolpidem users were identified as patients who used zolpidem during the enrollment period. The index date was the date of the first zolpidem prescription. Dosage of zolpidem use was defined using cumulative defined daily dose (cDDD) based on the cumulative dosage that patients took within one year after the index date (grouped as: less than 28, 28–90, 91–180, and more than 180 cDDD). Measurements: The occurrence of Alzheimer's disease was defined as the time period from the end of one year after the index date to the date of the Alzheimer's disease diagnosis. The propensity score was used to adjust the measured confounders of Alzheimer's disease. Cox proportional hazards models were used to evaluate the association between zolpidem use and the incidence of Alzheimer's disease. Results: Zolpidem users with a high cumulative dose (>180 cDDD) in the first year after initiation had a significantly greater risk of Alzheimer's disease than non-zolpidem users (HR = 2.97, 95% CI = 1.61–5.49) and low cumulative dose (<28 cDDD) users (HR = 4.18, 95% CI = 1.77–9.86). Conclusion: We found the use of a high cumulative dose of zolpidem was associated with an increased risk of Alzheimer's disease among older people living in Taiwan. It is advised to use caution when considering long-term use of zolpidem in older patients.

KW - Alzheimer's disease

KW - hypnotics

KW - National Health Insurance Research Database (NHIRD)

KW - Taiwan

KW - zolpidem

UR - http://www.scopus.com/inward/record.url?scp=85034081882&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034081882&partnerID=8YFLogxK

U2 - 10.1111/jgs.15018

DO - 10.1111/jgs.15018

M3 - Article

C2 - 28884784

AN - SCOPUS:85034081882

VL - 65

SP - 2488

EP - 2495

JO - Journal of the American Geriatrics Society

JF - Journal of the American Geriatrics Society

SN - 0002-8614

IS - 11

ER -